FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097240274> ?p ?o ?g. }

• W2097240274 endingPage "2664" @default.
• W2097240274 startingPage "2657" @default.
• W2097240274 abstract "BACKGROUND The importance of human epidermal growth factor receptor 2 (HER2) as a prognostic and predictive marker in invasive breast cancer is well established. Accurate assessment of HER2 status is essential to determine optimal treatment options. METHODS Breast cancer tumor tissue samples from the VIRGO observational cohort tissue substudy that were locally HER2-negative were retested centrally with both US Food and Drug Administration (FDA)-approved immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assays, using FDA-approved assay cutoffs; results were compared. RESULTS Of the 552 unique patient samples centrally retested with local HER2-negative results recorded, tumor samples from 22 (4.0%) patients were determined to be HER2-positive (95% confidence interval [CI] = 2.5%-5.7%). Of these, 18 had been tested locally by only one testing methodology; 15 of 18 were HER2-positive after the central retesting, based on the testing methodology not performed locally. Compared with the 530 patients with centrally confirmed HER2-negative tumors, the 22 patients with centrally determined HER2-positive tumors were younger (median age 56.5 versus 60.0 years) and more likely to have ER/PR-negative tumors (27.3% versus 22.3%). These patients also had shorter median progression-free survival (6.4 months [95% CI = 3.8-15.9 months] versus 9.1 months [95% CI = 8.3-10.3 months]) and overall survival (25.9 months [95% CI = 13.8-not estimable] versus 27.9 months [95% CI = 25.0-32.9 months]). CONCLUSIONS This study highlights the limitations of employing just one HER2 testing methodology in current clinical practice. It identifies a cohort of patients who did not receive potentially efficacious therapy because their tumor HER2-positivity was not determined by the test initially used. Because of inherent limitations in testing methodologies, it is inadvisable to rely on a single test to rule out potential benefit from HER2-targeted therapy. Cancer 2014;120:2657–2664. © 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society." @default.
• W2097240274 created "2016-06-24" @default.
• W2097240274 creator A5009555227 @default.
• W2097240274 creator A5012838192 @default.
• W2097240274 creator A5014192243 @default.
• W2097240274 creator A5022422153 @default.
• W2097240274 creator A5025364402 @default.
• W2097240274 creator A5030502460 @default.
• W2097240274 creator A5032187510 @default.
• W2097240274 creator A5060139738 @default.
• W2097240274 creator A5063391135 @default.
• W2097240274 creator A5067203408 @default.
• W2097240274 creator A5072015843 @default.
• W2097240274 creator A5072308451 @default.
• W2097240274 creator A5090188675 @default.
• W2097240274 creator A5090926486 @default.
• W2097240274 date "2014-06-13" @default.
• W2097240274 modified "2023-10-06" @default.
• W2097240274 title "Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer" @default.
• W2097240274 cites W1484094220 @default.
• W2097240274 cites W1531560418 @default.
• W2097240274 cites W1973135077 @default.
• W2097240274 cites W1977102289 @default.
• W2097240274 cites W1981593536 @default.
• W2097240274 cites W2017383394 @default.
• W2097240274 cites W2037392079 @default.
• W2097240274 cites W2064347883 @default.
• W2097240274 cites W2098775844 @default.
• W2097240274 cites W2099630695 @default.
• W2097240274 cites W2101979288 @default.
• W2097240274 cites W2104337757 @default.
• W2097240274 cites W2104872563 @default.
• W2097240274 cites W2107413762 @default.
• W2097240274 cites W2110444464 @default.
• W2097240274 cites W2110842243 @default.
• W2097240274 cites W2112621891 @default.
• W2097240274 cites W2113500453 @default.
• W2097240274 cites W2130900820 @default.
• W2097240274 cites W2141393790 @default.
• W2097240274 cites W2141546964 @default.
• W2097240274 cites W2146384083 @default.
• W2097240274 cites W2149773268 @default.
• W2097240274 cites W2149908785 @default.
• W2097240274 cites W2156677665 @default.
• W2097240274 cites W2159459001 @default.
• W2097240274 cites W2159967578 @default.
• W2097240274 cites W2165948908 @default.
• W2097240274 cites W2166199281 @default.
• W2097240274 cites W2318605753 @default.
• W2097240274 doi "https://doi.org/10.1002/cncr.28710" @default.
• W2097240274 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4232097" @default.
• W2097240274 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24930388" @default.
• W2097240274 hasPublicationYear "2014" @default.
• W2097240274 type Work @default.
• W2097240274 sameAs 2097240274 @default.
• W2097240274 citedByCount "45" @default.
• W2097240274 countsByYear W20972402742014 @default.
• W2097240274 countsByYear W20972402742015 @default.
• W2097240274 countsByYear W20972402742016 @default.
• W2097240274 countsByYear W20972402742017 @default.
• W2097240274 countsByYear W20972402742018 @default.
• W2097240274 countsByYear W20972402742019 @default.
• W2097240274 countsByYear W20972402742020 @default.
• W2097240274 countsByYear W20972402742021 @default.
• W2097240274 countsByYear W20972402742022 @default.
• W2097240274 countsByYear W20972402742023 @default.
• W2097240274 crossrefType "journal-article" @default.
• W2097240274 hasAuthorship W2097240274A5009555227 @default.
• W2097240274 hasAuthorship W2097240274A5012838192 @default.
• W2097240274 hasAuthorship W2097240274A5014192243 @default.
• W2097240274 hasAuthorship W2097240274A5022422153 @default.
• W2097240274 hasAuthorship W2097240274A5025364402 @default.
• W2097240274 hasAuthorship W2097240274A5030502460 @default.
• W2097240274 hasAuthorship W2097240274A5032187510 @default.
• W2097240274 hasAuthorship W2097240274A5060139738 @default.
• W2097240274 hasAuthorship W2097240274A5063391135 @default.
• W2097240274 hasAuthorship W2097240274A5067203408 @default.
• W2097240274 hasAuthorship W2097240274A5072015843 @default.
• W2097240274 hasAuthorship W2097240274A5072308451 @default.
• W2097240274 hasAuthorship W2097240274A5090188675 @default.
• W2097240274 hasAuthorship W2097240274A5090926486 @default.
• W2097240274 hasBestOaLocation W20972402741 @default.
• W2097240274 hasConcept C104317684 @default.
• W2097240274 hasConcept C121608353 @default.
• W2097240274 hasConcept C126322002 @default.
• W2097240274 hasConcept C143998085 @default.
• W2097240274 hasConcept C185592680 @default.
• W2097240274 hasConcept C204232928 @default.
• W2097240274 hasConcept C2777542201 @default.
• W2097240274 hasConcept C29456083 @default.
• W2097240274 hasConcept C30481170 @default.
• W2097240274 hasConcept C44249647 @default.
• W2097240274 hasConcept C530470458 @default.
• W2097240274 hasConcept C55493867 @default.
• W2097240274 hasConcept C71924100 @default.
• W2097240274 hasConcept C72563966 @default.
• W2097240274 hasConceptScore W2097240274C104317684 @default.
• W2097240274 hasConceptScore W2097240274C121608353 @default.

• next